Clinical Takeaway
In this phase 3 randomized controlled trial of 820 adults, the full-spectrum cannabis extract VER-01 was evaluated against placebo over 12 weeks for chronic low back pain, with longer-term follow-up extending to one year. The trial design meets the highest standard of clinical evidence, making its findings particularly relevant for patients and clinicians considering cannabis-based options when conventional treatments have provided inadequate relief.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a significant clinical gap by providing rigorous evidence for cannabis-based treatment in chronic low back pain, a condition affecting over 500 million people globally where current pharmacologic options demonstrate limited efficacy and considerable adverse effect profiles. The 12-week double-blind design with 820 participants offers the statistical power necessary to establish whether full-spectrum cannabis extract can serve as a viable alternative to conventional analgesics and opioids in managing this prevalent condition. If efficacious and well-tolerated, this medication could reduce opioid dependence and improve outcomes for patients who fail conventional therapy.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
🔬 This phase 3 trial of a full-spectrum cannabis extract for chronic low back pain addresses a genuine clinical need, given the limitations and risks of conventional analgesics, though several important considerations warrant careful interpretation. The study’s size and design are commendable, but the abstract’s incompleteness prevents assessment of critical outcomes, effect sizes, safety data, and whether benefits persisted in the open-label extension phase, which often shows inflated responses due to expectancy effects. Key confounders to consider include baseline pain severity, concurrent physical therapy or other treatments, the specific cannabinoid profile of VER-01, and whether outcomes were clinically meaningful rather than merely statistically significant. Before integrating this extract into practice, clinicians should await the full publication to evaluate tolerability, drug interactions particularly with common CLBP medications, and whether the effect magnitude justifies potential cognitive or driving safety concerns in their patient population. Until then, cannabis-based medicines for CLBP remain a reasonable consideration for carefully selected patients who have failed conventional
| |